2023
Prognosis and risk of suicide after cancer diagnosis
Kinslow C, Kumar P, Olfson M, Wall M, Petridis P, Horowitz D, Wang T, Kachnic L, Cheng S, Prigerson H, Yu J, Neugut A. Prognosis and risk of suicide after cancer diagnosis. Cancer 2023, 130: 588-596. PMID: 38018695, DOI: 10.1002/cncr.35118.Peer-Reviewed Original ResearchConceptsRisk of suicideCancer diagnosisSuicide riskCancer sitesMonths of diagnosisRelative risk of suicideSuicide deathsBaseline suicide riskSuicide ratesNewly diagnosed cancerYears of follow-upImpact of prognosisExistential distressAssociated with suicide riskMortality ratioWeighted linear regression modelImpending deathLinear regression modelsUS populationRelative riskGeneral populationBaseline riskAssociated with overall prognosisEnd Results databaseOverall survival ratePrognosis and risk of suicide after cancer diagnosis.
Kinslow C, Kumar P, Wall M, Prigerson H, Olfson M, Kachnic L, Horowitz D, Yu J, Cheng S, Neugut A. Prognosis and risk of suicide after cancer diagnosis. Journal Of Clinical Oncology 2023, 41: 6634-6634. DOI: 10.1200/jco.2023.41.16_suppl.6634.Peer-Reviewed Original ResearchRisk of suicideImpact of prognosisSuicide riskCancer sitesCancer diagnosisRelative risk of suicideBaseline riskNewly diagnosed cancerYears of follow-upRates of suicideMortality ratioU.S. cancersMonths of diagnosisWeighted linear regression modelLinear regression modelsPsychiatric referralRelative riskU.S. populationPersons ageTriage patientsSuicide ratesEnd ResultsBaseline rateIncreased surveillanceRegression models
2016
Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer
Lester-Coll N, Johnson S, Magnuson W, Goldhaber S, Sher D, D'Amico A, Yu J. Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. Journal Of The National Cancer Institute 2016, 109: djw281. PMID: 28040795, DOI: 10.1093/jnci/djw281.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerQuality-adjusted life yearsHormone therapyHistory of myocardial infarctionCardiac risk factorsBiochemical failureProstate cancerRadiation therapyCardiac riskProbability of biochemical failureMonths of hormone therapyRisk factorsMyocardial infarctionYears of follow-upBenefits of HTRisk of cardiovascular mortalityDisease recurrence riskCardiac risk groupsComparing quality-adjusted life-yearsYoung menRecurrence riskFollow-upRisk groupsCardiovascular mortalityLow risk